Molecular Partners AG operates as a clinical-stage biopharmaceutical company, focuses on the discovery, development, and commercialization of therapeutic proteins. Its products candidates include Abicipar, a DARPin therapeutic candidate, which is in Phase III clinical trials for the treatment of neovascular wet age-related macular degeneration, as well as for diabetic macular edema; and MP0420, a multi-specific DARPin therapeutic candidate for the SARS-CoV-2 virus. The company develops MP0310, which is in Phase Ia clinical trials for immuno-oncology; MP0317, a tumor-localized immune agonist that activates immune cells in the tumor, which is in Phase I clinical trials; and MP0274 that is in Phase I clinical trials for HER2-positive cancers. It also develops MP0423 for treating COVID-19; MP0533, a CD3 T cell candidate for acute myeloid leukemia; and MP0250 for vascular endothelial growth factor, hepatocyte growth factor, and human serum albumin to increase half-life. Molecular Partners AG has agreements and collaboration with Novartis AG to develop, manufacture, and commercialize DARPin-conjugated radioligand therapies; Amgen SA; Allergan, Inc.; and discovery alliance with AbbVie Inc. in ophthalmology, as well as other third-party collaborators. The company was incorporated in 2004 and is headquartered in Schlieren, Switzerland.
IPO Year: 2021
Exchange: NASDAQ
Website: https://www.molecularpartners.com
| Date | Price Target | Rating | Analyst |
|---|---|---|---|
| 8/30/2022 | Outperform → Sector Perform | RBC Capital Mkts | |
| 8/29/2022 | $30.00 → $8.00 | Outperform → Mkt Perform | SVB Leerink |
| 5/25/2022 | Underperform → Neutral | Credit Suisse | |
| 4/27/2022 | Neutral → Underperform | Credit Suisse |
EFFECT - MOLECULAR PARTNERS AG (0001745114) (Filer)
6-K - MOLECULAR PARTNERS AG (0001745114) (Filer)
6-K - MOLECULAR PARTNERS AG (0001745114) (Filer)
20-F - MOLECULAR PARTNERS AG (0001745114) (Filer)
6-K - MOLECULAR PARTNERS AG (0001745114) (Filer)
6-K - MOLECULAR PARTNERS AG (0001745114) (Filer)
6-K - MOLECULAR PARTNERS AG (0001745114) (Filer)
6-K - MOLECULAR PARTNERS AG (0001745114) (Filer)
424B5 - MOLECULAR PARTNERS AG (0001745114) (Filer)
6-K - MOLECULAR PARTNERS AG (0001745114) (Filer)
SC 13D/A - MOLECULAR PARTNERS AG (0001745114) (Subject)
SC 13D - MOLECULAR PARTNERS AG (0001745114) (Subject)
SC 13G/A - MOLECULAR PARTNERS AG (0001745114) (Subject)
SC 13G/A - MOLECULAR PARTNERS AG (0001745114) (Subject)
Positive IND-enabling data on MP0712 targeting DLL3, the most advanced Radio-DARPin program in co-development with Orano Med, entering clinical development in 2025 First preclinical data of novel targeted Radio-DARPin against mesothelin (MSLN), in co-development with Orano Med Additional preclinical proof-of-concept data on logic-gated CD3 Switch-DARPin T cell engager with CD2 co-stimulation ZURICH-SCHLIEREN, Switzerland and CONCORD, Mass., April 25, 2025 (GLOBE NEWSWIRE) -- Ad hoc announcement pursuant to Art. 53 LR Molecular Partners AG ((SIX: MOLN, NASDAQ:MOLN), a clinical-stage biotech company developing a new class of custom-built protein drugs known as DARPin therapeutics ("Mo
ZURICH-SCHLIEREN, Switzerland and CONCORD, Mass., April 16, 2025 (GLOBE NEWSWIRE) -- Molecular Partners AG ((SIX: MOLN, NASDAQ:MOLN), a clinical-stage biotech company developing a new class of custom-built protein drugs known as DARPin therapeutics ("Molecular Partners" or the "Company"), today announced that all motions proposed by the Board of Directors at the Annual General meeting were approved by the shareholders of the Company by a wide majority. The Molecular Partners shareholders confirmed the approval of the annual review, the IFRS consolidated financial statements and the annual statements for the financial year 2024. They also approved the consultative vote on the compensation
Update on IND-enabling data for MP0712, a Radio-DARPin targeting DLL3 and labeled with 212Pb, co-developed with Orano Med; entering FIH studies in 2025 for the treatment of small cell lung cancer First preclinical data on second 212Pb-based Radio-DARPin co-developed with Orano Med, targeting the membrane-proximal region of mesothelin (MSLN) in solid tumors Additional preclinical proof-of-concept data on CD3 Switch-DARPin T cell engager with CD2 co-stimulation in solid tumors ZURICH-SCHLIEREN, Switzerland and CONCORD, Mass., March 25, 2025 (GLOBE NEWSWIRE) -- Molecular Partners AG ((SIX: MOLN, NASDAQ:MOLN), a clinical-stage biotech company developing a new class of custom-built protein
ZURICH-SCHLIEREN, Switzerland and CONCORD, Mass., March 25, 2025 (GLOBE NEWSWIRE) -- Molecular Partners AG ((SIX: MOLN, NASDAQ:MOLN), a clinical-stage biotech company developing a new class of custom-built protein drugs known as DARPin therapeutics, today published the invitation to the Annual General Meeting 2025. The Annual General Meeting will be held on Wednesday, April 16, 2025, 9.00 CET (doors open at 8.30 CET), at JED Events, Zürcherstrasse 39, 8952 Schlieren, Switzerland. Invitation to the Annual General Meeting 2025 with the corresponding agenda items Einladung zur Generalversammlung 2025 mit den zugehörigen Traktandenpunkten Financial calendar April 16, 2025Annual General Me
Participation in fireside chats at TD Cowen and Leerink healthcare conferencesCall on 2024 financial results on March 7 at 2.00 pm CET (8.00 am ET) ZURICH-SCHLIEREN, Switzerland and CONCORD, Mass., Feb. 28, 2025 (GLOBE NEWSWIRE) -- Molecular Partners AG ((SIX: MOLN, NASDAQ:MOLN), a clinical-stage biotech company developing a new class of custom-built protein drugs known as DARPin therapeutics ("Molecular Partners" or the "Company"), today announced its attendance and presentations at upcoming investor conferences. Molecular Partners will also host a conference call on March 7 on its full-year 2024 financial report. The Annual Report is due to be published March 6. Details of the events:
New agreement enables both companies to fuel a broad and innovative pipeline of 212Pb-Radio-DARPin candidates, bringing the total number of programs up to tenExpanded partnership highlights the parties' emerging leadership in targeted alpha therapies (TAT), leveraging Orano Med's expertise in the development of 212Pb-based TAT and vast proprietary supply of 212Pb and Molecular Partners' unique Radio-DARPins as an ideal vector for radiopharmaceuticalsMost advanced 212Pb-Radio-DARPin, DLL3-targeted MP0712, starts clinical trials in 2025 ZURICH-SCHLIEREN, Switzerland and CONCORD, Mass., and PARIS, Jan. 12, 2025 (GLOBE NEWSWIRE) -- Ad hoc announcement pursuant to Art. 53 LR – Molecular Partn
Radio-DARPin MP0712 against DLL3, in co-development with Orano Med, to enter first-in-human study in 2025Mesothelin named as second target in Radio-DARPin pipeline, program to be co-developed with Orano MedOrano Med partnership on Radio-DARPins now expanded to 10 programsMP0533 clinical data show improved response rate and depth in cohort 8 with steeper step-up and more frequent dosing; additional dose densification planned in cohort 9, updates expected in 2025CD3 Switch-DARPin research proof-of-concept of conditional T cell activation and CD2 co-stimulation shown in solid tumors, further data in Q2 2025 ZURICH-SCHLIEREN, Switzerland and CONCORD, Mass., Jan. 12, 2025 (GLOBE NEWSWIRE) -- A
ZURICH-SCHLIEREN, Switzerland and CONCORD, Mass., Dec. 17, 2024 (GLOBE NEWSWIRE) -- Molecular Partners AG ((SIX: MOLN, NASDAQ:MOLN), a clinical-stage biotech company developing a new class of custom-built protein drugs known as DARPin therapeutics ("Molecular Partners" or the "Company"), today announced it will attend and present the Company's latest developments and outlook for 2025 at two upcoming investor conferences in January. Baader Helvea Swiss Equities Conference, taking place January 8-10 in Bad Ragaz, Switzerland Chief Operating Officer Alexander Zürcher to present on Wednesday, January 8 at the Grand Resort Bad Ragaz. 43rd Annual JP Morgan Healthcare Conference, January 13-16
MP0533 phase 1/2a dose escalation study continues with overall acceptable safety profile to date as well as initial antileukemic and pharmacodynamic activity Clinical protocol amendment in process with optimized dosing scheme to overcome target-mediated drug disposition and test the full potential of MP0533 Switch-DARPin MP0621 demonstrates intended mechanism in vivo, achieving killing of cKit+ cells while reducing off-target effects seen with systemic anti-CD47 blockade ZURICH-SCHLIEREN, Switzerland and CONCORD, Mass., Dec. 08, 2024 (GLOBE NEWSWIRE) -- Ad hoc announcement pursuant to Art. 53 LR – Molecular Partners AG ((SIX: MOLN, NASDAQ:MOLN), a clinical-stage biotech company de
Preclinical proof-of-concept data supports the potential of CD3 Switch-DARPin platform to activate and boost T cells in the presence of tumor targets only MP0317's ability to activate CD40 in a variety of tumor types further evidenced by comprehensive clinical biomarker analyses ZURICH-SCHLIEREN, Switzerland and CONCORD, Mass., Nov. 07, 2024 (GLOBE NEWSWIRE) -- Molecular Partners AG ((SIX: MOLN, NASDAQ:MOLN), a clinical-stage biotech company developing a new class of custom-built protein drugs known as DARPin therapeutics ("Molecular Partners" or the "Company"), today announced the presentation of data pertaining to two programs, including preclinical proof-of-concept for a novel T cell
RBC Capital Mkts downgraded Molecular Partners AG from Outperform to Sector Perform
SVB Leerink downgraded Molecular Partners AG from Outperform to Mkt Perform and set a new price target of $8.00 from $30.00 previously
Credit Suisse upgraded Molecular Partners AG from Underperform to Neutral
Credit Suisse downgraded Molecular Partners AG from Neutral to Underperform
Participation in fireside chats at TD Cowen and Leerink healthcare conferencesCall on 2024 financial results on March 7 at 2.00 pm CET (8.00 am ET) ZURICH-SCHLIEREN, Switzerland and CONCORD, Mass., Feb. 28, 2025 (GLOBE NEWSWIRE) -- Molecular Partners AG ((SIX: MOLN, NASDAQ:MOLN), a clinical-stage biotech company developing a new class of custom-built protein drugs known as DARPin therapeutics ("Molecular Partners" or the "Company"), today announced its attendance and presentations at upcoming investor conferences. Molecular Partners will also host a conference call on March 7 on its full-year 2024 financial report. The Annual Report is due to be published March 6. Details of the events:
ZURICH-SCHLIEREN, Switzerland and CONCORD, Mass., March 01, 2024 (GLOBE NEWSWIRE) -- Molecular Partners AG ((SIX: MOLN, NASDAQ:MOLN), a clinical-stage biotech company developing a new class of custom-built protein drugs known as DARPin therapeutics, today announced that it will issue its fourth quarter and full year financial results for 2023 on March 14, which will be followed by a conference call the next day to discuss the results. Molecular Partners' Chief Executive Officer Patrick Amstutz will also present at the 44th Annual Cowen Health Care Conference taking place in Boston, MA, and will participate in the Leerink Global Biopharma Conference taking place in Miami, FL along with oth
Phase 1/2a clinical trial of tetraspecific T cell engager candidate MP0533 initiated in patients with relapsed/refractory AML and MDS/AML; dosing ongoing in the 4th dose cohort; initial data expected in Q4 2023 Positive MP0317 data of ongoing Phase 1 clinical trial presented at ASCO confirm proposed MOA and indicates favorable safety profile in patients with advanced solid tumors, supporting future combination studies with potential partners; presently finalizing recruitment of weekly dosing regimen Preclinical data supporting the Radio DARPin Therapy platform presented at leading conferences TAT12, AACR and SNMMI in H1 2023 Funded well into 2026 with cash of CHF 218 million as of June 30
Research & Development Highlights: Initiated Phase 1 study of MP0533, a novel tri-specific T-cell engager for the treatment of acute myeloid leukemia (AML) and high risk myelodysplastic syndrome (MDS)Presented preclinical data supporting the unique design and mechanism of MP0533 at the 64th American Society of Hematology (ASH) Annual Meeting and ExpositionEstablished Radio DARPin Therapy (RDT) Platform, formally selecting tumor-associated protein Delta-like ligand 3 (DLL3) as a first targetPresented interim safety and mechanism data from ongoing Phase 1 study of MP0317 for the treatment of solid tumors at the 37th Society for Immunotherapy of Cancer (SITC) Annual MeetingSigned in early Janu
ZURICH-SCHLIEREN, Switzerland and CONCORD, Mass., March 02, 2023 (GLOBE NEWSWIRE) -- Molecular Partners AG ((SIX: MOLN, NASDAQ:MOLN), a clinical-stage biotech company developing a new class of custom-built protein drugs known as DARPin therapeutics, will issue a press release summarizing its highlights and financial results for the fourth quarter and full year of 2022, followed by an investor call the following day. Chief Executive Officer Patrick Amstutz will also deliver a company presentation at the 43rd Annual Cowen Health Care Conference in Boston, MA. Please see all details below: Conference Presentation Details: Cowen Health Care ConferenceMarch 8, 2023, at 9:10am ET (3:10pm CET)B
Continued development of MP0317, with initial clinical data from Phase 1 study expected in the second half of 2022Initiation of Phase 1 study for MP0533 expected by year endContinued progression of proprietary DARPin-conjugated radioligand therapeutics; innate immune cell engagers; next-generation T-cell engagers; and antiviral DARPinsMP0310 Phase 1 enrollment complete; no additional studies currently plannedIn January 2022, Molecular Partners received a payment of CHF 150 million from Novartis to license ensovibepNovartis is responsible for further development, manufacturing, and commercialization activities. An application for Emergency Use Authorization (EUA) was submitted to the U.S. Foo
ZURICH-SCHLIEREN, Switzerland and CONCORD, Mass., Aug. 18, 2022 (GLOBE NEWSWIRE) -- Molecular Partners AG ((SIX: MOLN, NASDAQ:MOLN), a clinical-stage biotech company developing a new class of custom-built protein drugs known as DARPin therapeutics, will issue a press release summarizing its highlights and financial results for the first half-year of 2022, followed by an analyst & investor call the following day. Please see more details here: Release date and time August 25, 2022, 4:30 pm ET (10:30 pm CET) Call Details: August 26, 2022, 8:00 am ET (2:00 pm CET) The half year 2022 results presentation will be webcast live and will be made available on the Company's website under the inv
ZURICH-SCHLIEREN, Switzerland and CONCORD, Mass., Feb. 25, 2022 (GLOBE NEWSWIRE) -- Molecular Partners AG ((SIX: MOLN, NASDAQ:MOLN), a clinical-stage biotech company developing a new class of custom-built protein drugs known as DARPin therapeutics, today announced that its Chief Executive Officer, Patrick Amstutz, Ph.D., will participate in two upcoming healthcare investor events in March, 2022. In addition, the Company will publish its full year 2021 annual report on March 15 and hold an investor conference call on March 16, 2021. Presentation Details: Cowen Health Care Conference – Fireside chat Wednesday, March 9, 2022 at 2:10-2:40pm ET Conference Participation Detai